TGFB1 and non-small cell lung carcinoma: Pirfenidone, an FDA-approved drug for idiopathic pulmonary fibrosis, inhibits the production of TGFb1 and collagen, reduces tumor growth, and increases T-cell and NK-cell infiltration in murine non-small-cell lung cancer (NSCLC) [19].